Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
FB102 antibody treatment for nonsegmental vitiligo
Official title: A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-Segmental Vitiligo
Status: Recruiting now
Description:
Forte Biosciences, Inc. plans to enroll about 64 participants. FB102 is an experimental antibody that targets CD122 and changes IL-2 and IL-15 immune signaling. It is intended to reduce disease-driving T-cell activity so melanocytes can recover and repigment the skin. Possible risks include infusion reactions, headache, and infections; early studies have mainly reported mild or moderate events. People ages 18 to 75 may qualify. The study is recruiting at 6 listed sites in Australia, and New Zealand.
Start date: March 25, 2025
Completion date: December 31, 2026
Organizer: Forte Biosciences, Inc.
Contact: Cindy Kok
Tel.: +61 2 8651 2042
Email: ckok@skinhospital.edu.au
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Белые пятна на теле? Витилиго?
Гид по Витилиго — ваш компас в лабиринте загадочной болезни и непростых решений. Здесь всё по-честному, по делу и на понятном языке. Вы найдёте здесь: Объяснения, что происходи...
- Is there a traditional medicine to treat vitiligo?
Traditional remedies can be helpful for managing stress or general metabolic health, but when it comes to vitiligo, the evidence is limited. While some natural supplements provi...
- Who is prone to vitiligo?
Vitiligo can affect anyone, regardless of gender, age, or race. Vitiligo prevalence is between 0.76% and 1.11% of the U.S. population, including around 40% of those with the con...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.